nct_id,url,brief_title,official_title,enrollment,agency,f_name,l_name,phone,email,Other Study Contact,country,condition
NCT05712772,https://clinicaltrials.gov/ct2/show/NCT05712772,Neuro-affective Response to Light in Depressed Adolescents and Young Adults,Neuro-affective Response to Light in Depressed Adolescents and Young Adults,80,University of Pittsburgh,Adriane,Soehner,4122466651,soehneram2@upmc.edu,Allison Caswell,United States,"Depression in Adolescence
Depression in Adults"
NCT05712772,https://clinicaltrials.gov/ct2/show/NCT05712772,Neuro-affective Response to Light in Depressed Adolescents and Young Adults,Neuro-affective Response to Light in Depressed Adolescents and Young Adults,80,University of Pittsburgh,Allison,Caswell,4122466652,caswella@upmc.edu,Adriane M Soehner,United States,"Depression in Adolescence
Depression in Adults"
NCT05712759,https://clinicaltrials.gov/ct2/show/NCT05712759,Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period,"Surveillance of Nosocomial Influenza at Edouard Herriot University Hospital, Lyon, France",350,Hospices Civils de Lyon,Philippe,VANHEMS,0472110719,philippe.vanhems@chu-lyon.fr,Laetitia HENAFF,,Infection Viral
NCT05712759,https://clinicaltrials.gov/ct2/show/NCT05712759,Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period,"Surveillance of Nosocomial Influenza at Edouard Herriot University Hospital, Lyon, France",350,Hospices Civils de Lyon,Laetitia,HENAFF,0472110719,laetitia.henaff@chu-lyon.fr,Philippe VANHEMS,,Infection Viral
NCT05712746,https://clinicaltrials.gov/ct2/show/NCT05712746,Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.,Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.,"1,600","Otsuka Pharmaceutical Co., Ltd.",Pharmacovigilance,Department Otsuka Pharmaceutical Co.,+81-6-6943-7722,komaniwa.satoshi@otsuka.jp,Yasuhiko Fukuta,Not United States,Heart Failure
NCT05712746,https://clinicaltrials.gov/ct2/show/NCT05712746,Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.,Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.,"1,600","Otsuka Pharmaceutical Co., Ltd.",Yasuhiko,Fukuta,,,Pharmacovigilance Department Otsuka Pharmaceutical Co.,Not United States,Heart Failure
NCT05712733,https://clinicaltrials.gov/ct2/show/NCT05712733,Cholecystitis From a Microbiological and Histopathological Perspective,Cholecystitis From a Microbiological and Histopathological Perspective,60,"Organkirurgisk afdeling, sygehus lillebælt, Kolding",Malene,Dissing,004528745840,malene.borgager@rsyd.dk,Louise L Pontoppidan,,"Calculous Cholecystitis
Antibiotic Resistant Infection
Gallbladder Inflammation"
NCT05712733,https://clinicaltrials.gov/ct2/show/NCT05712733,Cholecystitis From a Microbiological and Histopathological Perspective,Cholecystitis From a Microbiological and Histopathological Perspective,60,"Organkirurgisk afdeling, sygehus lillebælt, Kolding",Louise,Pontoppidan,004527124689,louise.lerche.pontoppidan2@rsyd.dk,Malene B Dissing,,"Calculous Cholecystitis
Antibiotic Resistant Infection
Gallbladder Inflammation"
NCT05712707,https://clinicaltrials.gov/ct2/show/NCT05712707,Sublingual Dexmedetomidine for Treating Opioid Withdrawal,"Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal",160,New York State Psychiatric Institute,Gabriela,Madera,646-774-6119,Gabriela.Madera@nyspi.columbia.edu,Sandra Comer,,"Opioid Use Disorder
Opioid Withdrawal"
NCT05712707,https://clinicaltrials.gov/ct2/show/NCT05712707,Sublingual Dexmedetomidine for Treating Opioid Withdrawal,"Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal",160,New York State Psychiatric Institute,Jermaine,Jones,646-774-6613,jermaine.jones@nyspi.columbia.edu,Sandra Comer,,"Opioid Use Disorder
Opioid Withdrawal"
NCT05712707,https://clinicaltrials.gov/ct2/show/NCT05712707,Sublingual Dexmedetomidine for Treating Opioid Withdrawal,"Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal",160,New York State Psychiatric Institute,Sandra,Comer,,,Gabriela Madera,,"Opioid Use Disorder
Opioid Withdrawal"
NCT05712694,https://clinicaltrials.gov/ct2/show/NCT05712694,Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC),"ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial",300,Polaris Group,Mirla,Langlois,858-452-6688,mlanglois@polarispharma.com,John S Bomalaski,,Soft Tissue Sarcoma
NCT05712694,https://clinicaltrials.gov/ct2/show/NCT05712694,Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC),"ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial",300,Polaris Group,Stephanie,Rumund,858-452-6688,svanrumund@polarispharma.com,John S Bomalaski,,Soft Tissue Sarcoma
NCT05712694,https://clinicaltrials.gov/ct2/show/NCT05712694,Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC),"ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial",300,Polaris Group,John,Bomalaski,,,Mirla Langlois,,Soft Tissue Sarcoma
NCT05712473,https://clinicaltrials.gov/ct2/show/NCT05712473,An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer,A Prospective Observational Multicenter Real-World Registry Assessing the Impact of the Use of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer,500,PPsanalytics,Lorraine,ODonnell,19143884907,lorraine.odonnell@ppsanalytics.com,,,Prostate Cancer
NCT05712434,https://clinicaltrials.gov/ct2/show/NCT05712434,Chlorhexidine to Prevent Catheter-related Urinary Tract Infection,"A Multi-center, Stepped-wedge, Cluster-randomized Control Trial to Evaluation the Effectiveness of Chlorhexidine to Prevent Catheter-associated Urinary Tract Infection","15,000",National Taiwan University Hospital,Guan-Jhou,Chen,+886-3-3179599,guanjhouchen@ntu.edu.tw,Yee-Chun Chen,,Urinary Tract Infections
NCT05712434,https://clinicaltrials.gov/ct2/show/NCT05712434,Chlorhexidine to Prevent Catheter-related Urinary Tract Infection,"A Multi-center, Stepped-wedge, Cluster-randomized Control Trial to Evaluation the Effectiveness of Chlorhexidine to Prevent Catheter-associated Urinary Tract Infection","15,000",National Taiwan University Hospital,Yee-Chun,Chen,,,Guan-Jhou Chen,,Urinary Tract Infections
NCT05712382,https://clinicaltrials.gov/ct2/show/NCT05712382,Promoting Maintenance of Change Following Brief Intervention for Alcohol Use,Promoting Maintenance of Change Following Brief Intervention for Alcohol Use,160,"University of Massachusetts, Amherst",Allecia,Reid,413-545-0264,aereid@umass.edu,,,"Young Adult(M01.060.116.815)
Students(M01.848)
Risk Reduction Behavior (F01.145.699)
Alcohol Drinking (F01.145.317.269)
Health Promotion (I02.233.332.445)"
NCT05712356,https://clinicaltrials.gov/ct2/show/NCT05712356,A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors,"A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors",120,"Lisata Therapeutics, Inc.",Kathryn,Shantz,484-437-6500,kshantz@lisata.com,Kristen K Buck,,"Esophageal Cancer
Head and Neck Squamous Cell Carcinoma
Advanced Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Cholangiocarcinoma
Esophageal Squamous Cell Carcinoma
Gallbladder Cancer
Gallbladder Carcinoma
Intrahepatic Cholangiocarcinoma
Extrahepatic Cholangiocarcinoma"
NCT05712356,https://clinicaltrials.gov/ct2/show/NCT05712356,A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors,"A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors",120,"Lisata Therapeutics, Inc.",Kristen,Buck,,,Kathryn Shantz,,"Esophageal Cancer
Head and Neck Squamous Cell Carcinoma
Advanced Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Cholangiocarcinoma
Esophageal Squamous Cell Carcinoma
Gallbladder Cancer
Gallbladder Carcinoma
Intrahepatic Cholangiocarcinoma
Extrahepatic Cholangiocarcinoma"
NCT05712343,https://clinicaltrials.gov/ct2/show/NCT05712343,The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis,The Efficacy of Systemic Valacyclovir (Valtrex) to Arrest Further Progression of Severe Periodontitis,40,"University of California, San Francisco",Mike,Sabeti,415-476-0822,mike.sabeti@ucsf.edu,,United States,Severe Periodontitis
NCT05712304,https://clinicaltrials.gov/ct2/show/NCT05712304,Impact of SE of the Proximal Colon on the MAR,"Impact of the Second vs. Conventional Examination of the Proximal Colon on Adenoma Miss Rate, a Prospective Randomized Tandem Trial",420,Third People's Hospital of Jingdezhen City,xiaojia,zhu,15879497590,zhuxiaojia2021@163.com,li yang,,Adenoma Miss Rate
NCT05712304,https://clinicaltrials.gov/ct2/show/NCT05712304,Impact of SE of the Proximal Colon on the MAR,"Impact of the Second vs. Conventional Examination of the Proximal Colon on Adenoma Miss Rate, a Prospective Randomized Tandem Trial",420,Third People's Hospital of Jingdezhen City,li,yang,,,xiaojia zhu,,Adenoma Miss Rate
NCT05712252,https://clinicaltrials.gov/ct2/show/NCT05712252,Risk Factors for Fall and Fracture,Risk Factors for Fall and Fracture. A Cohort Study of Fall-related Factors Obtained in Routine Orthopaedic Fracture Care,800,Region Skane,Cecilia,Rogmark,+4640336123,cecilia.rogmark@med.lu.se,,,"Fall Injury
Hip Fractures
Risk Reduction
Osteoporosis, Osteopenia
Frailty"
NCT05712174,https://clinicaltrials.gov/ct2/show/NCT05712174,A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer,A Phase II Study of Fluorine-18 (18F)-Labeled PSMA-1007 in Patients With Known or Suspected Metastatic Prostatic Carcinoma,248,AHS Cancer Control Alberta,Stella,Koumna,780-577-8080,stella.koumna@albertahealthservices.ca,,Not United States,"Oncology
Prostate Cancer"
NCT05712135,https://clinicaltrials.gov/ct2/show/NCT05712135,Investigation of Endotracheal Cuff Pressure Changes According to Different Positions in Neurosurgery Cases,Investigation of Endotracheal Cuff Pressure Changes According to Different Positions in Neurosurgery Cases,165,Ankara City Hospital Bilkent,Sena,Sarıcaoglu Oktem,+90 538 600 2190,senasaricaoglu@gmail.com,Mehmet Sahap,,The Effect of Cuff Pressure on Postoperative Dysphagia
NCT05712135,https://clinicaltrials.gov/ct2/show/NCT05712135,Investigation of Endotracheal Cuff Pressure Changes According to Different Positions in Neurosurgery Cases,Investigation of Endotracheal Cuff Pressure Changes According to Different Positions in Neurosurgery Cases,165,Ankara City Hospital Bilkent,Mehmet,Sahap,+90 533 682 6254,drsahap@gmail.com,Sena Sarıcaoglu Oktem,,The Effect of Cuff Pressure on Postoperative Dysphagia
NCT05712096,https://clinicaltrials.gov/ct2/show/NCT05712096,eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services,An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among Immunocompromised Patients in Israel,"4,000",AstraZeneca,AstraZeneca,Clinical Study Information Center,1-877-240-9479,information.center@astrazeneca.com,,,"SARS-CoV-2
COVID-19"
NCT05712070,https://clinicaltrials.gov/ct2/show/NCT05712070,Mobile Application for Cardiovascular Risk Treatment,Impact of Smart Watch Mobile Application on Risk Treatment of CardioVascular Disease,450,Asan Medical Center,Soo-Jin,Kang,+82230103157,sjkang3157@gmail.com,Tae-Oh Kim,,"Hypertension
Hyperlipidemias
Chronic Disease
Lifestyle Risk Reduction"
NCT05712070,https://clinicaltrials.gov/ct2/show/NCT05712070,Mobile Application for Cardiovascular Risk Treatment,Impact of Smart Watch Mobile Application on Risk Treatment of CardioVascular Disease,450,Asan Medical Center,Tae-Oh,Kim,+82230103150,allldie@hanmail.net,Soo-Jin Kang,,"Hypertension
Hyperlipidemias
Chronic Disease
Lifestyle Risk Reduction"
NCT05712057,https://clinicaltrials.gov/ct2/show/NCT05712057,Neurostimulation Versus Therapy for Problems With Emotions,Neurostimulation Enhanced Cognitive Restructuring for Transdiagnostic Emotional Dysregulation: A Component Analysis,240,Duke University,Andrada,Neacsiu,9196846714,andrada.neacsiu@duke.edu,Lisalynn D Kelley,United States,"Emotion Regulation
Mood Disorders
Stress Disorder
Anxiety Disorders
OCD
Impulse Control Disorder
Eating Disorders
Emotional Dysfunction
Emotional Instability
Emotional Distress
Emotional Maladjustment
Emotional Impulsivity
Obsessive-Compulsive Disorder
Emotion Dysregulation"
NCT05712057,https://clinicaltrials.gov/ct2/show/NCT05712057,Neurostimulation Versus Therapy for Problems With Emotions,Neurostimulation Enhanced Cognitive Restructuring for Transdiagnostic Emotional Dysregulation: A Component Analysis,240,Duke University,Lisalynn,Kelley,9196846701,lisalynn.kelley@duke.edu,Andrada D Neacsiu,United States,"Emotion Regulation
Mood Disorders
Stress Disorder
Anxiety Disorders
OCD
Impulse Control Disorder
Eating Disorders
Emotional Dysfunction
Emotional Instability
Emotional Distress
Emotional Maladjustment
Emotional Impulsivity
Obsessive-Compulsive Disorder
Emotion Dysregulation"
NCT05712044,https://clinicaltrials.gov/ct2/show/NCT05712044,Effect of Folic Acid on the Presentation of Nuclear Abnormalities in People With a History Drug Abuse,Evaluation of the Effect of Folic Acid Supplementation on the Presentation of Nuclear Abnormalities Associated With Cytogenotoxic Damage Induced by Chronic Drug Use.,45,Centro Universitario de Tonalá,Alejandro,Gomez,3319955964,alex-gomez96@hotmail.com,Guadalupe Sanchez,Not United States,"Drug Abuse
Genotoxicity"
NCT05712044,https://clinicaltrials.gov/ct2/show/NCT05712044,Effect of Folic Acid on the Presentation of Nuclear Abnormalities in People With a History Drug Abuse,Evaluation of the Effect of Folic Acid Supplementation on the Presentation of Nuclear Abnormalities Associated With Cytogenotoxic Damage Induced by Chronic Drug Use.,45,Centro Universitario de Tonalá,Francisco,Rodriguez,3317055900,franciscomora1097@gmail.com,Guadalupe Sanchez,Not United States,"Drug Abuse
Genotoxicity"
NCT05712044,https://clinicaltrials.gov/ct2/show/NCT05712044,Effect of Folic Acid on the Presentation of Nuclear Abnormalities in People With a History Drug Abuse,Evaluation of the Effect of Folic Acid Supplementation on the Presentation of Nuclear Abnormalities Associated With Cytogenotoxic Damage Induced by Chronic Drug Use.,45,Centro Universitario de Tonalá,Guadalupe,Sanchez,,,Alejandro Gomez,Not United States,"Drug Abuse
Genotoxicity"
NCT05712018,https://clinicaltrials.gov/ct2/show/NCT05712018,Comparison of Different HES Coload Volumes on the 90% ED of Norepinephrine,Comparison of Different 6% Hydroxyethyl Starch (130/0.4) Coload Volumes on the 90% Effective Dose of Norepinephrine Infusion Prophylaxis for Hypotension During Spinal Anesthesia for Cesarean Section,120,General Hospital of Ningxia Medical University,Yi,Chen,86-951-674-3252,czzyxgp@163.com,Xiangsheng Xiong,,Adverse Effect
NCT05712018,https://clinicaltrials.gov/ct2/show/NCT05712018,Comparison of Different HES Coload Volumes on the 90% ED of Norepinephrine,Comparison of Different 6% Hydroxyethyl Starch (130/0.4) Coload Volumes on the 90% Effective Dose of Norepinephrine Infusion Prophylaxis for Hypotension During Spinal Anesthesia for Cesarean Section,120,General Hospital of Ningxia Medical University,Xiangsheng,Xiong,,158193942@qq.com,Yi Chen,,Adverse Effect
NCT05711992,https://clinicaltrials.gov/ct2/show/NCT05711992,Rare Embryonal Tumors of the Central Nervous System: International Registry,Rare Embryonal Tumors of the Central Nervous System: International Registry,300,Immune Oncology Research Institute,Julieta,Hoveyan,+374 10 28 38 00,julia.hoveyan95@gmail.com,Ruzanna Papyan,Not United States,Embryonal Tumor
NCT05711992,https://clinicaltrials.gov/ct2/show/NCT05711992,Rare Embryonal Tumors of the Central Nervous System: International Registry,Rare Embryonal Tumors of the Central Nervous System: International Registry,300,Immune Oncology Research Institute,Ruzanna,Papyan,+374 10 28 38 00,ruzannapapyan92@gmail.com,Ruzanna Papyan,Not United States,Embryonal Tumor
NCT05711992,https://clinicaltrials.gov/ct2/show/NCT05711992,Rare Embryonal Tumors of the Central Nervous System: International Registry,Rare Embryonal Tumors of the Central Nervous System: International Registry,300,Immune Oncology Research Institute,Gevorg,Tamamyan,,,Ruzanna Papyan,Not United States,Embryonal Tumor
NCT05711927,https://clinicaltrials.gov/ct2/show/NCT05711927,Sleep in SNOO Smart Sleeper Bassinet in Preterm Infants,The Effect of Sleeping Environment on Sleep-Wake Organization in Preterm Infants,50,Columbia University,Toni,Iurcotta,646-532-8196,ti2241@cumc.columbia.edu,Rakesh Sahni,United States,"Prematurity
Very Preterm Maturity of Infant"
NCT05711927,https://clinicaltrials.gov/ct2/show/NCT05711927,Sleep in SNOO Smart Sleeper Bassinet in Preterm Infants,The Effect of Sleeping Environment on Sleep-Wake Organization in Preterm Infants,50,Columbia University,Rakesh,Sahni,,,Toni Iurcotta,United States,"Prematurity
Very Preterm Maturity of Infant"
NCT05711849,https://clinicaltrials.gov/ct2/show/NCT05711849,Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina,A Phase II Randomised Sham-controlled Trial Assessing the Safety and Efficacy of Intracoronary Administration of Autologous Bone Marrow Cells in Patients With Refractory Angina,110,Barts & The London NHS Trust,R&D,Governance Administrator,+44 (0)20 7882 6826,research.governance@qmul.ac.uk,Anthony Mathur,Not United States,Refractory Angina Pectoris
NCT05711849,https://clinicaltrials.gov/ct2/show/NCT05711849,Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina,A Phase II Randomised Sham-controlled Trial Assessing the Safety and Efficacy of Intracoronary Administration of Autologous Bone Marrow Cells in Patients With Refractory Angina,110,Barts & The London NHS Trust,Anthony,Mathur,,,R&D Governance Administrator,Not United States,Refractory Angina Pectoris
NCT05711823,https://clinicaltrials.gov/ct2/show/NCT05711823,Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC,ApRepitant in Combination With Granisetron and Dexamethasone versUs Granisetron and dexamEthasone for the Prevention of Vomiting in Patients With HAIC Therapy for Hepatocellular Carcinoma: a Randomized Controlled Study (ARGUE),300,Guangxi Medical University,Jian-Hong,Zhong,+86 771 5301253,zhongjianhong66@163.com,Le-Qun Li,,Hepatocellular Carcinoma
NCT05711823,https://clinicaltrials.gov/ct2/show/NCT05711823,Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC,ApRepitant in Combination With Granisetron and Dexamethasone versUs Granisetron and dexamEthasone for the Prevention of Vomiting in Patients With HAIC Therapy for Hepatocellular Carcinoma: a Randomized Controlled Study (ARGUE),300,Guangxi Medical University,Liang,Ma,+86 771 5301253,malianggxyd@163.com,Le-Qun Li,,Hepatocellular Carcinoma
NCT05711823,https://clinicaltrials.gov/ct2/show/NCT05711823,Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC,ApRepitant in Combination With Granisetron and Dexamethasone versUs Granisetron and dexamEthasone for the Prevention of Vomiting in Patients With HAIC Therapy for Hepatocellular Carcinoma: a Randomized Controlled Study (ARGUE),300,Guangxi Medical University,Le-Qun,Li,,,Jian-Hong Zhong,,Hepatocellular Carcinoma
NCT05711784,https://clinicaltrials.gov/ct2/show/NCT05711784,"A Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract)","A Randomized, Double-blinded, Placebo-controlled, Single-Centre, Comparative, Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract).",66,NovoBliss Research Pvt Ltd,Maheshvari,Patel,91-9909013236,maheshvari@novobliss.in,Dr Nayan K Patel,Not United States,Body Weight in the Overweight and Obese Class - I Population
NCT05711784,https://clinicaltrials.gov/ct2/show/NCT05711784,"A Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract)","A Randomized, Double-blinded, Placebo-controlled, Single-Centre, Comparative, Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract).",66,NovoBliss Research Pvt Ltd,Sheetal,Khandwala,,bd@novobliss.in,Dr Nayan K Patel,Not United States,Body Weight in the Overweight and Obese Class - I Population
NCT05711784,https://clinicaltrials.gov/ct2/show/NCT05711784,"A Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract)","A Randomized, Double-blinded, Placebo-controlled, Single-Centre, Comparative, Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract).",66,NovoBliss Research Pvt Ltd,Dr,Nayan Patel,,,Maheshvari N Patel,Not United States,Body Weight in the Overweight and Obese Class - I Population
NCT05711719,https://clinicaltrials.gov/ct2/show/NCT05711719,Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction,Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction,45,Johns Hopkins University,Thorsten,Leucker,410-502-9453,tleucke1@jhmi.edu,Gary Gerstenblith,United States,"Metabolic Syndrome
Coronary Microvascular Dysfunction"
NCT05711719,https://clinicaltrials.gov/ct2/show/NCT05711719,Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction,Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction,45,Johns Hopkins University,Gary,Gerstenblith,410-955-6835,gblith@jhmi.edu,Thorsten M Leucker,United States,"Metabolic Syndrome
Coronary Microvascular Dysfunction"
NCT05711706,https://clinicaltrials.gov/ct2/show/NCT05711706,Su Jok Application in After Lumbar Disc Surgery,"The Effect of Su Jok Application on Pain, Anxiety and Quality of Recovery After Lumbar Disc Surgery",60,Niran Çoban,Niran,COBAN,05301586912,nirancoban@gmail.com,Niran Çoban,Not United States,"Pain, Postoperative
Lumbar Disc Herniation
Surgery
Nurse's Role"
NCT05711706,https://clinicaltrials.gov/ct2/show/NCT05711706,Su Jok Application in After Lumbar Disc Surgery,"The Effect of Su Jok Application on Pain, Anxiety and Quality of Recovery After Lumbar Disc Surgery",60,Niran Çoban,Niran,Çoban,05301586912,nirancoban@gmail.com,Niran COBAN,Not United States,"Pain, Postoperative
Lumbar Disc Herniation
Surgery
Nurse's Role"
NCT05711693,https://clinicaltrials.gov/ct2/show/NCT05711693,Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV),Integrated Silicon Photonics for Cardiovascular Disease Monitoring InSiDe-CC Clinical Validation of the Diagnostic Device (LDV) for the Measurement of Heart-carotid Pulse Wave Velocity (PWV) by Magnetic Resonance Imaging (MRI),100,"Institut National de la Santé Et de la Recherche Médicale, France",Pierre,Boutouyrie,0156093991,pierre.boutouyrie@aphp.fr,,,"Hypertension
Aortic Aneurysm
Bicuspid Aortic Valve
Marfan Syndrome
Aortic Dilatation"
NCT05711563,https://clinicaltrials.gov/ct2/show/NCT05711563,Predicting and Monitoring Outcomes in Autoimmune Encephalitis,Predicting and Monitoring Outcomes in Autoimmune Encephalitis,50,"Royal College of Surgeons, Ireland",Mark,Kelly,+353 1 809 2210,markkelly22@rcsi.com,Norman Delanty,,Autoimmune Encephalitis
NCT05711563,https://clinicaltrials.gov/ct2/show/NCT05711563,Predicting and Monitoring Outcomes in Autoimmune Encephalitis,Predicting and Monitoring Outcomes in Autoimmune Encephalitis,50,"Royal College of Surgeons, Ireland",Norman,Delanty,+353 1 809 2210,normandelanty@beaumont.ie,Mark Kelly,,Autoimmune Encephalitis
NCT05711524,https://clinicaltrials.gov/ct2/show/NCT05711524,Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding,Pilot Clinical Trial of Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen (INTERCEPT Fibrinogen Complex) in Patients With Bleeding to Expedite Product Availability and Improve Outcomes in Perioperative Bleeding,302,Weill Medical College of Cornell University,Melissa,Cushing,212-746-3527,mec2013@med.cornell.edu,Pranesh Rajendran,United States,"Hypofibrinogenemia
Bleeding"
NCT05711524,https://clinicaltrials.gov/ct2/show/NCT05711524,Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding,Pilot Clinical Trial of Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen (INTERCEPT Fibrinogen Complex) in Patients With Bleeding to Expedite Product Availability and Improve Outcomes in Perioperative Bleeding,302,Weill Medical College of Cornell University,Pranesh,Rajendran,212-746-1810,prr4005@med.cornell.edu,Melissa Cushing,United States,"Hypofibrinogenemia
Bleeding"
NCT05711446,https://clinicaltrials.gov/ct2/show/NCT05711446,Double Voiding and Post-transplant UTI,A Randomized Trial of Double Voiding Versus Usual Voiding to Reduce the Incidence of Urinary Tract Infections in Kidney Transplant Recipients,438,Weill Medical College of Cornell University,Muthukumar,Thangamani,212-746-9074,mut9002@med.cornell.edu,Tierra Mack,United States,"Urinary Tract Infections
Kidney Transplant; Complications"
NCT05711446,https://clinicaltrials.gov/ct2/show/NCT05711446,Double Voiding and Post-transplant UTI,A Randomized Trial of Double Voiding Versus Usual Voiding to Reduce the Incidence of Urinary Tract Infections in Kidney Transplant Recipients,438,Weill Medical College of Cornell University,Tierra,Mack,212-746-6112,tmm4004@med.cornell.edu,Muthukumar Thangamani,United States,"Urinary Tract Infections
Kidney Transplant; Complications"
NCT05711407,https://clinicaltrials.gov/ct2/show/NCT05711407,Peri-implantitis and MMP-8,"The Relationship of Peri-implantitis With COX-2 Gene Polymorphisms, Active MMP-8 Levels, and Characterization of Associated Microbiota.",100,Aristotle University Of Thessaloniki,Ioannis,Fragkioudakis,+306973381496,ifragkio@gmail.com,Dimitra Sakellari,,Peri-Implantitis
NCT05711407,https://clinicaltrials.gov/ct2/show/NCT05711407,Peri-implantitis and MMP-8,"The Relationship of Peri-implantitis With COX-2 Gene Polymorphisms, Active MMP-8 Levels, and Characterization of Associated Microbiota.",100,Aristotle University Of Thessaloniki,Dimitra,Sakellari,,dimsak@dent.auth.gr,Ioannis Fragkioudakis,,Peri-Implantitis
NCT05711394,https://clinicaltrials.gov/ct2/show/NCT05711394,A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine,"A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.",450,AbbVie,ABBVIE,CALL CENTER,844-663-3742,abbvieclinicaltrials@abbvie.com,ABBVIE INC.,United States,Episodic Migraine
NCT05711394,https://clinicaltrials.gov/ct2/show/NCT05711394,A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine,"A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.",450,AbbVie,ABBVIE,INC.,,,ABBVIE CALL CENTER,United States,Episodic Migraine
NCT05711329,https://clinicaltrials.gov/ct2/show/NCT05711329,Comparison of Methodology Proposed by the SFAR for the Detection by Videoconference of Obstructive Sleep Apnea.,The Aim of This Study is to Determine the Accuracy of the Self-reported Parameters (Compared to Measurement Performed by the Physician) and the Influence of OSA Screening Scores.,210,Astes,Eric,Deflandre,003281209563,eric.deflandre@gmail.com,,,Obstructive Sleep Apnea
